戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 adation of cell membranes and thus premature device failure.
2 sulting in sensor performance compromise and device failure.
3 evolution of conduction channel and eventual device failure.
4 often hampered by specific complications and device failure.
5 aortic arch appear to be predictive of early device failure.
6 ic morphology was analyzed for predictors of device failure.
7 y malfunctions were the most common cause of device failure.
8 device malfunction and the likely effects of device failure.
9 most common reason for catheter exchange was device failure.
10 nsive, expensive, and burdensome sequelae of device failure.
11 rature rise and thermal stress, resulting in device failure.
12 esult in membrane delamination and, thereby, device failure.
13 e potential for bleeding, tissue damage, and device failure.
14 gnificantly contributes to complications and device failure.
15 r resulting in nanoscale hotspots leading to device failures.
16 nufacturers in identifying potentially fatal device failures.
17 ons [27.1%]) accounted for half of the total device failures.
18 q(3) as well as for crystallization-assisted device failures.
19 n a substrate which could cause catastrophic device failures.
20 discharge inefficiencies, and spurs complete device failure(1-3).
21 521 [2.3%]; aHR, 0.42; 95% CI, 0.13-1.40) or device failure (40 of 675 [5.9%] vs 48 of 521 [9.2%]; aH
22 ed toxicity (12 pts., 17%), and irreversible device failure (5 pts., 7%).
23 fe of batteries, which increases the risk of device failure and causes uncertainty among patients.
24  may be associated with a lower incidence of device failure and infection, but with more thromboembol
25 nts with BAV stenosis showed higher rates of device failure and periprocedural complications as compa
26 gher rate of complications, higher chance of device failure, and worse visual outcomes than observed
27  logistic regression identified only closure device failure as an independent predictor of a vascular
28 probability of survival free from stroke and device failure at 2 years as compared with a pulsatile d
29                                              Device failure can be mitigated by using encapsulation m
30                                     However, device failure can occur gradually and start months afte
31 thrombophlebitis, or exit site concerns) and device failure, defined as catheter removal following de
32           The primary outcome was time until device failure, defined as intraocular pressure (IOP) >2
33            The primary outcome was all-cause device failure, defined as premature cessation of device
34 ral catheters (PICCs) may reduce the risk of device failure due to infectious, thrombotic, and cathet
35 ere referred for PICC placement, the risk of device failure due to noninfectious or infectious compli
36  crystal stress increased the probability of device failure from 6 to 20%, while an inhomogeneous car
37                                              Device failure from diffusion short circuits in microele
38                     High-profile implantable device failures have fuelled concerns about the level of
39 nferior to the BGI with regard to time until device failure (hazard ratio [HR], 0.83; confidence inte
40  risk, 1.58 [95%CI: 0.91-2.73], P=0.133) and device failure in 4.7% versus 5.4% (relative risk, 0.86,
41 xpected increases resulting from respiratory device failures in community-based patients.
42                                        Early device failure is associated with sharp angulation of th
43 owever, BCP interlayers has shown to lead to device failure, mainly due to the clustering of BCP mole
44                                  Respiratory device failure (mechanical ventilators, positive pressur
45                                              Device failure occurred in 21 of 358 participants (5.9%)
46  examine the life expectancy, breakdown, and device failure of engineered skeletal muscle bio-bots as
47 evice failure rate and the likely effects of device failure on mortality.
48 welve late deaths have occurred, none due to device failure or AAA rupture.
49                            There has been no device failure or hemolysis.
50 heter mitral valve repair had AKI, linked to device failure or other severe conditions.
51                           There were no late device failures or complications.
52 s severe bleeding, limb ischemia, hemolysis, device failure, or worsening aortic regurgitation.
53 epends primarily on the advisory's estimated device failure rate and the likely effects of device fai
54  to a low, but potentially life-threatening, device failure rate found during postoperative testing.
55   For pacemaker-dependent patients, advisory device failure rates exceeding 0.3% warrant device repla
56 in the study group had device malfunction or device failure requiring replacement (16.2% vs. 8.8%), a
57 ing contacts leads to energy dissipation and device failure, resulting in massive economic and enviro
58 ients with ICDs, SD directly attributable to device failure seems to be rare.
59 fibrillator (ICD) shocks are associated with device failure, significant morbidity, and increased mor
60                                Infection and device failure still limit the safety of long periods of
61 undesirable thermal runaway effects and even device failure through self-heating.
62                    Differences in time until device failure, VA outcomes, and medication use were inc
63 ndard-polyurethane group, the odds ratio for device failure was 0.96 (95% CI, 0.51 to 1.78), and in t
64 minutes [IQR, 1.0-2.0]; P <.001) and closure device failure was also significantly lower among those
65  of adverse cardiovascular events related to device failure was found in both groups.
66                                              Device failure was lower in patients in the MC group (10
67             Risks of minor complications and device failure were similar across device types.
68 ntion has been given to predicting premature device failure where the device fails within several hun
69                      The primary outcome was device failure, which was a composite of infectious (blo
70 so discusses strategies for managing closure device failure, with the goal of minimizing vascular com